Abstracts

High Frequency of HEV Seropositivity in HIV-Infected Patients in Southern Spain

Background: HEV has been reported to be a cause chronic liver disease with rapid progression to cirrhosis in HIV-infected patients. Anti-HEV seropositivity has been observed in 9% HIV carriers in Northern Spain. Likewise rates of seropositivity of 2.6% and 4% have been reported in HIV-infected patients with unexplained transaminase elevation in Switzerland and France respectively.…

Immunogenicity and Reactogenicity of Cervarix*®* Versus Gardasil*®* in HIV-Infected Adults: An RCT

Background: Most human papillomavirus (HPV)-related cancers are potentially vaccine-preventable. Persons infected with HIV have excess risk of developing HPV-related cancers but are often hyporesponsive to immunization. We hypothesized that in HIV-infected adults the TLR4 agonist-adjuvanted bivalent HPV vaccine would be more immunogenic than the alum-adjuvanted quadrivalent HPV vaccine. Methodology: We performed an investigator-initiated, double-blind, controlled…

HIV Inhibition and Variation in Anti-Microbial Peptides Associated With Intercourse

Background: Anti-microbial peptides (AMP) in vaginal fluid play a key role in vaginal mucosal immunity but dynamic effects have not been documented. Since penile-vaginal intercourse (PVI) is an important HIV transmission route, variation in AMP levels could affect HIV inhibition and likelihood of infection. This study documents levels of several AMPs – trappin, human beta-defensin…

Influence of RAL vs Boosted ATZ-based Regimens on Cervical Immune Reconstitution and Activation

Background: A significant amount of HIV-related morbidity has been attributable to genital tract disease in women. It is established that tenofovir (TDF), emtricitabine (FTC), and raltegravir (RAL) have high genital concentrations while atazanavir/ritonavir (ATZ) has more modest levels. We examine if RAL vs ATZ-based regimen is superior with respect to improved cervical immune reconstitution and…